Manufactured under a pharmaceutical license to ensure gold-standard compliance, KETOJOL™ 4:1 combines prebiotics, improved palatability, and enhanced nutrition for Drug-Resistant Epilepsy.

NATIONAL, INDIA – In a major breakthrough for clinical nutrition and pediatric neurology, Jolly Healthcare  today announced the national launch of KETOJOL™ 4:1. Standardized to a precise 4:1 fat-to-(protein + carbohydrate) ratio, KETOJOL™ marks a monumental category milestone as India’s first ketogenic diet formulation. Setting a new benchmark for clinical integrity, the product is manufactured under a specialized pharmaceutical license, guaranteeing gold-standard quality, safety, and precise formulation distinct from standard food-grade manufacturing.

Understanding Drug-Resistant Epilepsy and Ketogenic Therapy

Drug-Resistant Epilepsy (DRE) affects nearly one in three epilepsy patients, who continue to suffer from uncontrolled seizures despite multi-drug Anti-Epileptic Drug (AED) therapy. Published clinical literature establishes that classical Ketogenic Dietary Therapy (KDT) — delivering 90% of total calories from fat — can achieve a ≥50% reduction in seizure frequency in 50–60% of refractory pediatric cases by utilizing ketones as an alternative energy source to stabilize neuronal hyperexcitability.

Leadership Statement on the Launch

Addressing the landmark launch, Mr. Avish Jolly, MD & CEO of Jolly Healthcare, stated:

“For decades, families managing Drug-Resistant Epilepsy have faced severe execution barriers — from complex home calculations and poor pediatric palatability to long-term nutritional deficits and gastrointestinal distress. By securing classification under a pharmaceutical manufacturing license, KETOJOL™ 4:1 bridges the gap between strict clinical efficacy and real-world compliance. Enhanced with prebiotics (Inulin) for superior GI tolerance and formulated for child acceptance, our goal is to empower pediatric neurologists and dietitians with a practical, high-precision solution that supports uninterrupted childhood.”

How KETOJOL™ 4:1 Addresses Clinical Limitations

Engineered as a comprehensive medical nutrition solution, KETOJOL™ 4:1 addresses the key clinical limitations of traditional ketogenic diets. The inclusion of prebiotics (Inulin) improves gastrointestinal tolerance, while its enriched micronutrient profile helps mitigate long-term nutritional deficiencies commonly associated with strict ketogenic regimens.

Rollout Strategy and Caregiver Support Programme

Jolly Healthcare is executing an institution-first rollout across tertiary care hospitals, paediatric neurology centres, and specialized dietetic clinics. The launch is supported by the ‘KETOJOL™ Keto Support Program‘, providing precision digital weighing protocols (0.1g accuracy) and caregiver education to ensure exact dosage administration.

KETOJOL™ 4:1 is intended for use under qualified medical supervision as an adjunct dietary therapy alongside prescribed clinical management.